Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MAY 2018. Refer to TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | abiraterone acetate (Zytiga®) | ||
| Formulation | 250 mg tablet | ||
| Reference number | 1794 | ||
| Indication | In combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Full | ||
| Status | Superseded | ||
| Advice number | 1614 | ||
| NMG meeting date | 09/04/2014 | ||
| AWMSG meeting date | 11/06/2014 | ||
| Ratification by Welsh Government | 01/09/2014 | ||
| Date of issue | 25/09/2014 | ||
| NICE guidance | |||
| Commercial arrangement | CAA | ||
| Further information Technologies recommended by NICE that include a commercial arrangement |
|||